TESARO (NASDAQ: TSRO) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare TESARO to related companies based on the strength of its analyst recommendations, institutional ownership, earnings, profitability, dividends, valuation and risk.
This is a summary of recent ratings and recommmendations for TESARO and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
TESARO currently has a consensus price target of $158.57, indicating a potential upside of 88.79%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 47.07%. Given TESARO’s higher possible upside, research analysts plainly believe TESARO is more favorable than its competitors.
Risk & Volatility
TESARO has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Comparatively, TESARO’s competitors have a beta of 5.58, suggesting that their average share price is 458% more volatile than the S&P 500.
Insider & Institutional Ownership
50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 40.5% of TESARO shares are held by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares TESARO and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares TESARO and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|TESARO||$44.82 million||-$387.47 million||-9.95|
|TESARO Competitors||$284.28 million||$34.29 million||134.64|
TESARO’s competitors have higher revenue and earnings than TESARO. TESARO is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
TESARO competitors beat TESARO on 8 of the 12 factors compared.
TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.
Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.